


# Patent Claims

## 1. Compounds formula I



in which

15 A denotes a mono- or bicyclic aromatic or non-aromatic carba- or heterocyclic ring system which is unsubstituted or mono- or polysubstituted by R<sup>1</sup>,

20 R<sub>1</sub> denotes H, Hal, NO<sub>2</sub>, NHR, NRR, OR, CO-R, SO<sub>3</sub>R, SO<sub>2</sub>R, SR, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl,

R<sub>2</sub> denotes H, Hal, NO<sub>2</sub>, NHR, NRR, OR, CO-R, SO<sub>3</sub>R, SO<sub>2</sub>R, SR, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl,

25 R<sub>3</sub> denotes C<sub>1</sub>-C<sub>8</sub> alkyl,

X denotes CO, CS, SO<sub>2</sub>,

Y denotes a single bond, O, NH, CH<sub>2</sub>

30 R denotes H or a C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl or C<sub>7</sub>-C<sub>14</sub> aralkyl group, which may be mono- or polysubstituted by R<sub>5</sub> and whose alkyl-C chain may be interrupted by -O-,

35 Hal denotes F, Cl, Br, or I


m denotes 0, 1, 2, 3 or 4

and

n denotes 0, 1, 2 or 3,

5 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, exclusively mixtures thereof in all ratios.

## 2. Compounds of the formula IA



in which  $R^1$ ,  $R^2$ ,  $R^3$ , X, Y, A, m and n have the meaning indicated in Claim 1, and pharmacological usable derivatives, salts, solvates and stereoisomers thereof and mixtures thereof in all ratios.

## 3. Compound of the formula I and IA, according to Claim 1 or 2 in which

A denotes phenyl, pyridyl, thienyl or cyclohexyl, each of which is unsubstituted or mono- or polysubstituted by  $R^1$ ,

25  $R^1$  denotes H

$R^2$  denotes H or Hal.

## 4. Medicament of the formula I according to one or more of Claims 1, 2 or 3 in which

A denotes phenyl or naphthyl

35 and/or

X denotes CO or SO<sub>2</sub>

and/or

Y denotes a single bond or NH.

5

10

5. Use of the compounds of the formula I and/or IA according to Claims 1-4 and physiologically acceptable salts, solvates and derivatives thereof for the preparation of medicaments for the treatment and/or prophylaxis of irritable bowel syndrome.

15

6. Pharmaceutical composition, characterised by a content of at least one compound of the formula I and/or IA and/or one of its physiologically acceptable salts, solvates and derivatives according to one of Claims 1 to 4 for the treatment and/or prophylaxis of irritable bowel syndrome.

20

7. Compounds of the formula I according to Claim 1 to 4 and acceptable salts, solvates and derivatives thereof as medicaments.

25

8. Use of the compounds of the formula I and/or IA according to Claim 1 to 4 and physiologically acceptable salts, solvates and derivatives thereof for the preparation of medicaments for the treatment and/or prophylaxis of diseases which can be influenced by kappa agonists.

30

9. Medicament formulation comprising at least one compound of the formula I and or IA according to one or more of the preceding claims and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

35